Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t
The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments
- Supported exchanges /
- F /
- BRM.F
Bristol-Myers Squibb Company (BRM F) stock market data APIs
€50.87
0.2(0.4%)
as of November 1, 2024
Price chart is built with Anychart
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol-Myers Squibb Company Financial Data Overview
| 50.67 | |
| 50.87 | |
| - | |
| 51.26 | |
| 50.29 | |
| 35.8976-51.26 | |
| 103 495 M | |
| 2 028 M | |
| 46 509 M | |
| 0.0453 | |
| 0.46 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'BRM',
Type:
'Common Stock',
Name:
'Bristol-Myers Squibb Company',
Exchange:
'F',
CurrencyCode:
'EUR',
CurrencyName:
'Euro',
CurrencySymbol:
'€',
CountryName:
'Germany',
CountryISO:
'DE',
OpenFigi:
NULL,
ISIN:
NULL,
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Drug Manufacturers - General',
CUSIP:
NULL,
}
Bristol-Myers Squibb Company Fundamental Data is available in our Financial Data APIs
- Net Revenue 46 509 M
- EBITDA 19 048 M
- Earnings Per Share -3.29
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Bristol-Myers Squibb Company Earnings via APIs
- Latest Release 2024-10-31
- EPS/Forecast NaN
Get Bristol-Myers Squibb Company End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Bristol-Myers Squibb Company latest news via APIs
Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stock...
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
